PROGESTERONE- progesterone capsule

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

PROGESTERONE (UNII: 4G7DS2Q64Y) (PROGESTERONE - UNII:4G7DS2Q64Y)

제공처:

NuCare Pharmaceuticals,Inc.

INN (국제 이름):

PROGESTERONE

구성:

PROGESTERONE 100 mg

관리 경로:

ORAL

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea. Progesterone capsules should not be used in women with any of the following conditions: - Progesterone capsules should not be used in patients with known hypersensitivity to itsingredients. Progesterone capsules contain peanut oil and should never be used by patients allergic to peanuts. - Undiagnosed abnormal genital bleeding. - Known, suspected, or history of breast cancer. - Active deep vein thrombosis, pulmonary embolism or history of these conditions. - Active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions. - Known liver dysfunction or disease. - Known or suspected pregnancy.

제품 요약:

Progesterone, capsules 100 mg are available as an oval orange, opaque, capsule imprinted with P-1 in black ink. NDC 68071-2134-3 Bottle of 30 Store at 20-25°C (68-77°F). [See USP Controlled Room Temperature] Protect from excessive moisture Keep out of reach of children. Dispense in tight, light-resistant container as defined in USP/NF, accompanied by a Patient Insert. Manufactured by: Banner Pharmacaps Inc. High Point, NC 27265 November 2013

승인 상태:

Abbreviated New Drug Application

제품 특성 요약

PROGESTERONE- PROGESTERONE CAPSULE
NUCARE PHARMACEUTICALS,INC.
----------
BOXED WARNING
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE
DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY
CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA
Estrogens plus progestin therapy should not be used for the prevention
of cardiovascular disease
or dementia. (See CLINICAL STUDIESand WARNINGS, CARDIOVASCULAR
DISORDERS and
PROBABLE DEMENTIA.)
The Women's Health Initiative (WHI) estrogen plus progestin substudy
reported increased risks
of deep vein thrombosis, pulmonary embolism, stroke and myocardial
infarction in
postmenopausal women (50 to 79 years of age) during 5.6 years of
treatment with daily oral
conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone
acetate (MPA) [2.5
mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS,
CARDIOVASCULAR
DIS ORDERS .)
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study
of the WHI reported
an increased risk of developing probable dementia in postmenopausal
women 65 years of age or
older during 4 years of treatment with daily CE (0.625 mg) combined
with MPA (2.5 mg), relative
to placebo. It is unknown whether this finding applies to younger
postmenopausal women. (See
CLINICAL STUDIES and WARNINGS, PROBABLE DEMENTIA and PRECAUTIONS,
GERIATRIC
US E.)
BREAST CANCER
The WHI estrogen plus progestin substudy also demonstrated an
increased risk of invasive breast
cancer. (See CLINICAL STUDIES and WARNINGS, MALIGNANT NEOPLASMS,
_BREAST CANCER._)
In the absence of comparable data, these risks should be assumed to be
similar for other doses of
CE and MPA, and other combinations and dosage forms of estrogens and
progestins.
Progestins with estrogens should be prescribed at the lowest effective
doses and for the shortest
duration consistent with treatment goals and risks for the individual
woman.
DESCRIPTION
Progesterone USP, capsules contain micronized progesterone for oral
administration. Progesterone has
a molecular weight of 314.47 and a molecular formul